<DOC>
	<DOCNO>NCT02259010</DOCNO>
	<brief_summary>This study assess effect multi-dose administration itraconazole single-dose pharmacokinetics ( PK ) alisertib .</brief_summary>
	<brief_title>A Study Evaluate Effect Itraconazole Pharmacokinetics Alisertib Patients With Advanced Solid Tumors Relapsed/Refractory Lymphoma</brief_title>
	<detailed_description>The drug test study call alisertib . Alisertib test adult patient advance solid tumor relapse refactory lymphoma . The study look effect pharmacokinetics ( drug move body ) alisertib presence absence itraconazole . This open label study . Participants receive : - Alisertib tablets 30 mg Part A 50 mg Part B - Itraconazole oral solution 200 mg Part A Participation Part A 14 day . The maximum duration treatment alisertib 12 month ( approximately 16 cycle ) unless determine investigator , agreement sponsor , patient would derive clinical benefit continue treatment beyond 12 month . This multi-centre study take place United States .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female patient 18 year age old . 2 . Patients histologic cytologic diagnosis advance metastatic solid tumor lymphomas curative lifeprolonging therapy exist . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Exclusion Criteria 1 . Systemic treatment moderate strong CYP3A inhibitor inducer must discontinue least 14 day first dose alisertib , use agent permit study ( except protocolspecified administration itraconazole ) . 2 . Known gastrointestinal ( GI ) abnormality ( include recurrent nausea vomit ) GI procedure could interfere modify oral absorption tolerance alisertib . 3 . Known hypersensitivity intolerance itraconazole similar class agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>